Intercellular NETwork-facilitated sarcoplasmic reticulum targeting for myocardial ischemia-reperfusion injury treatment

IF 12.5 1区 综合性期刊 Q1 MULTIDISCIPLINARY SCIENCES Science Advances Pub Date : 2025-02-12 DOI:10.1126/sciadv.adr4333
Peihang Jiang, Fangyang Huang, Liqiang Chen, Hao Zhou, Yudi Deng, Lian Li, Mao Chen, Yuan Huang
{"title":"Intercellular NETwork-facilitated sarcoplasmic reticulum targeting for myocardial ischemia-reperfusion injury treatment","authors":"Peihang Jiang, Fangyang Huang, Liqiang Chen, Hao Zhou, Yudi Deng, Lian Li, Mao Chen, Yuan Huang","doi":"10.1126/sciadv.adr4333","DOIUrl":null,"url":null,"abstract":"Myocardial ischemia-reperfusion injury (MIRI) often leads to irreversible myocardium dysfunction, while existing therapies are palliatives that transiently alleviate the disease symptoms. Repairing sarcoplasmic reticulum Ca <jats:sup>2+</jats:sup> -ATPase (SERCA) could reverse MIRI, which, however, requires precise drug delivery to the sarcoplasmic reticulum (SR). To this end, we leverage cell-cell “NETwork” of neutrophils to deliver SERCA activator-loaded SR-localized nanoparticles (L-P-NPs) to the damaged myocardial cells, following a hierarchical targeting process: (i) chemotactic neutrophils deliver L-P-NPs to ischemia-reperfused heart, achieving tissue level targeting; (ii) neutrophils produce neutrophil extracellular traps (NETs) to transport L-P-NPs to injured myocardial cell, achieving cellular level targeting; (iii) L-P-NPs escort therapeutic payloads to the SR, achieving subcellular targeting. We showed that this platform profoundly restored SERCA activity, augmented cardiac function, and ameliorated adverse heart remodeling. Our study provides insight into the direct restoration of SR for the effective treatment of MIRI and other muscle diseases.","PeriodicalId":21609,"journal":{"name":"Science Advances","volume":"41 1","pages":""},"PeriodicalIF":12.5000,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Science Advances","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.1126/sciadv.adr4333","RegionNum":1,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Myocardial ischemia-reperfusion injury (MIRI) often leads to irreversible myocardium dysfunction, while existing therapies are palliatives that transiently alleviate the disease symptoms. Repairing sarcoplasmic reticulum Ca 2+ -ATPase (SERCA) could reverse MIRI, which, however, requires precise drug delivery to the sarcoplasmic reticulum (SR). To this end, we leverage cell-cell “NETwork” of neutrophils to deliver SERCA activator-loaded SR-localized nanoparticles (L-P-NPs) to the damaged myocardial cells, following a hierarchical targeting process: (i) chemotactic neutrophils deliver L-P-NPs to ischemia-reperfused heart, achieving tissue level targeting; (ii) neutrophils produce neutrophil extracellular traps (NETs) to transport L-P-NPs to injured myocardial cell, achieving cellular level targeting; (iii) L-P-NPs escort therapeutic payloads to the SR, achieving subcellular targeting. We showed that this platform profoundly restored SERCA activity, augmented cardiac function, and ameliorated adverse heart remodeling. Our study provides insight into the direct restoration of SR for the effective treatment of MIRI and other muscle diseases.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
细胞间网络促进肌质网靶向治疗心肌缺血再灌注损伤
心肌缺血再灌注损伤(MIRI)往往导致不可逆的心肌功能障碍,而现有的治疗方法是暂时缓解疾病症状的姑息疗法。修复肌浆网ca2 + - atp酶(SERCA)可以逆转MIRI,然而,这需要精确的药物递送到肌浆网(SR)。为此,我们利用中性粒细胞的细胞-细胞“网络”将装载SERCA激活剂的sr定位纳米颗粒(L-P-NPs)递送到受损的心肌细胞,遵循分层靶向过程:(i)趋化中性粒细胞将L-P-NPs递送到缺血再灌注的心脏,实现组织水平靶向;(ii)中性粒细胞产生中性粒细胞胞外陷阱(NETs),将L-P-NPs转运到受损的心肌细胞,实现细胞水平靶向;(iii) L-P-NPs护送治疗有效载荷到SR,实现亚细胞靶向。我们发现,该平台深刻地恢复了SERCA活性,增强了心脏功能,并改善了不良的心脏重塑。我们的研究为直接恢复SR为有效治疗MIRI和其他肌肉疾病提供了新的思路。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
文献相关原料
公司名称
产品信息
索莱宝
4′,6-diamidino-2-phenylindole (DAPI)
索莱宝
PBS
索莱宝
trypsin
索莱宝
4′,6-diamidino-2-phenylindole (DAPI)
索莱宝
PBS
索莱宝
trypsin
麦克林
Luteolin
麦克林
Luteolin
麦克林
Luteolin
来源期刊
Science Advances
Science Advances 综合性期刊-综合性期刊
CiteScore
21.40
自引率
1.50%
发文量
1937
审稿时长
29 weeks
期刊介绍: Science Advances, an open-access journal by AAAS, publishes impactful research in diverse scientific areas. It aims for fair, fast, and expert peer review, providing freely accessible research to readers. Led by distinguished scientists, the journal supports AAAS's mission by extending Science magazine's capacity to identify and promote significant advances. Evolving digital publishing technologies play a crucial role in advancing AAAS's global mission for science communication and benefitting humankind.
期刊最新文献
Biased AI writing assistants shift users' attitudes on societal issues. A persistent-range hydrogen-bonded gel polymer electrolyte enabling wide-temperature and recyclable lithium metal batteries. 40 Tesla miniature magnets. Biodegradable targeted polymeric mRNA nanoparticles enable in vivo CD19 CAR T cell generation and lead to B cell depletion. Atmospheric systems drive spatiotemporal divergence of dust and moisture changes across Asia over the past 130,000 years.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1